CHANGE OF COMPANY SECRETARY

MELBOURNE (AUSTRALIA) 31 July 2024: Invion Limited (ASX: IVX) ("**Invion**" or the "**Company**") is pleased to announce the appointment of Mr Tai Phan as Company Secretary, effective immediately.

Mr Phan has over 20 years' experience as a lawyer, Company Secretary, and corporate governance and compliance professional. He has worked directly with Boards and executive management of several ASX-listed entities (i.e. Zip Co Limited, Westpac Banking Corp, HT&E Limited, and Yancoal Australia Ltd) and numerous unlisted companies across multiple industries. He has experience in the IPO listing process for the ASX, has been appointed an external consultant for AUSTRAC and as the Head of Asia-Pac Compliance (for Travelex and Munich Re).

Ms Claire Newstead-Sinclair will resign as Company Secretary of Invion, effective immediately. The Board wishes to thank Ms Newstead-Sinclair for her service to the Company.

Invion further advises that, in accordance with Listing Rule 12.6 and with immediate effect, Mr Phan is the person responsible for communications with ASX in relation to Listing Rule matters.

This announcement was approved for release by the Board of Invion Limited.

Investor and Media enquiries:

Thian Chew (Chairman & CEO)
T: +61 3 9692 7222
E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)
M: +61 409 341 613
E: brendon.lau@inviongroup.com

About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau, the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States, Canada and Hong Kong for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited. Invion is listed on the ASX (ASX: IVX).

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and

promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs".